Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
Sandoz reports Q1 2025 net sales of USD 2,480 million, showing 3% growth in constant currencies. The company maintains its full-year guidance, expecting mid single-digit net sales growth and a core EBITDA margin of around 21%.
Key performance highlights:
- Generics sales: USD 1,809 million (73% of total sales)
- Biosimilars sales: USD 671 million (27% of total sales)
- Europe net sales grew 7%
- International sales declined 2%
- North America sales grew 1%
The company plans major biosimilar launches in 2025, including Wyost/Jubbonti (denosumab) in Europe and US, Tyruko (natalizumab) in US, and Afqlir (aflibercept) in Europe. Recent US government tariffs impact includes a 20% China tariff implemented March 4, 2025, with effects within guidance expectations.
Sandoz comunica per il primo trimestre 2025 vendite nette pari a 2.480 milioni di USD, con una crescita del 3% a tassi di cambio costanti. L’azienda conferma le previsioni per l’intero anno, prevedendo una crescita delle vendite nette a una cifra media e un margine EBITDA core intorno al 21%.
Punti chiave delle performance:
- Vendite di farmaci generici: 1.809 milioni di USD (73% del totale)
- Vendite di biosimilari: 671 milioni di USD (27% del totale)
- Le vendite nette in Europa sono cresciute del 7%
- Le vendite internazionali sono diminuite del 2%
- Le vendite in Nord America sono cresciute dell’1%
L’azienda prevede importanti lanci di biosimilari nel 2025, tra cui Wyost/Jubbonti (denosumab) in Europa e Stati Uniti, Tyruko (natalizumab) negli Stati Uniti e Afqlir (aflibercept) in Europa. L’impatto delle recenti tariffe governative USA include un dazio del 20% sulla Cina entrato in vigore il 4 marzo 2025, con effetti all’interno delle aspettative di guida.
Sandoz reporta ventas netas en el primer trimestre de 2025 por 2.480 millones de USD, mostrando un crecimiento del 3% en monedas constantes. La empresa mantiene su pronóstico para todo el año, esperando un crecimiento de ventas netas de un dígito medio y un margen EBITDA core alrededor del 21%.
Aspectos destacados del desempeño:
- Ventas de genéricos: 1.809 millones de USD (73% del total de ventas)
- Ventas de biosimilares: 671 millones de USD (27% del total de ventas)
- Las ventas netas en Europa crecieron un 7%
- Las ventas internacionales disminuyeron un 2%
- Las ventas en Norteamérica crecieron un 1%
La compañía planea importantes lanzamientos de biosimilares en 2025, incluyendo Wyost/Jubbonti (denosumab) en Europa y EE. UU., Tyruko (natalizumab) en EE. UU. y Afqlir (aflibercept) en Europa. El impacto de los recientes aranceles del gobierno de EE. UU. incluye un arancel del 20% sobre China implementado el 4 de marzo de 2025, con efectos dentro de las expectativas del pronóstico.
Sandoz는 2025년 1분기 순매출이 24억 8천만 달러로, 환율 변동을 제외한 기준으로 3% 성장했다고 보고했습니다. 회사는 연간 가이던스를 유지하며, 중간 한 자릿수 순매출 성장과 약 21%의 핵심 EBITDA 마진을 예상하고 있습니다.
주요 실적 하이라이트:
- 제네릭 매출: 18억 900만 달러 (총 매출의 73%)
- 바이오시밀러 매출: 6억 7,100만 달러 (총 매출의 27%)
- 유럽 순매출 7% 성장
- 국제 매출 2% 감소
- 북미 매출 1% 성장
회사는 2025년에 Wyost/Jubbonti(데노수맙)를 유럽 및 미국에서, Tyruko(나탈리주맙)를 미국에서, Afqlir(아플리버셉트)를 유럽에서 주요 바이오시밀러 출시를 계획하고 있습니다. 최근 미국 정부의 관세 영향으로 2025년 3월 4일 시행된 중국산 제품에 대한 20% 관세가 포함되며, 이는 가이던스 예상 범위 내에 있습니다.
Sandoz annonce un chiffre d'affaires net au premier trimestre 2025 de 2,480 millions USD, affichant une croissance de 3 % en devises constantes. L’entreprise maintient ses prévisions annuelles, anticipant une croissance du chiffre d’affaires net à un chiffre moyen et une marge EBITDA core d’environ 21 %.
Points clés des performances :
- Ventes de génériques : 1 809 millions USD (73 % du total des ventes)
- Ventes de biosimilaires : 671 millions USD (27 % du total des ventes)
- Les ventes nettes en Europe ont augmenté de 7 %
- Les ventes internationales ont diminué de 2 %
- Les ventes en Amérique du Nord ont progressé de 1 %
L’entreprise prévoit des lancements majeurs de biosimilaires en 2025, notamment Wyost/Jubbonti (dénosumab) en Europe et aux États-Unis, Tyruko (natalizumab) aux États-Unis, et Afqlir (aflibercept) en Europe. L’impact des récents tarifs gouvernementaux américains inclut un tarif de 20 % sur la Chine mis en place le 4 mars 2025, avec des effets conformes aux attentes de la guidance.
Sandoz meldet für das erste Quartal 2025 einen Nettoumsatz von 2.480 Millionen USD und verzeichnet ein Wachstum von 3 % bei konstanten Wechselkursen. Das Unternehmen bestätigt seine Jahresprognose und erwartet ein Nettoumsatzwachstum im mittleren einstelligen Bereich sowie eine Kern-EBITDA-Marge von etwa 21 %.
Wichtige Leistungskennzahlen:
- Generika-Umsatz: 1.809 Millionen USD (73 % des Gesamtumsatzes)
- Biosimilars-Umsatz: 671 Millionen USD (27 % des Gesamtumsatzes)
- Nettoverkäufe in Europa stiegen um 7 %
- Internationale Verkäufe gingen um 2 % zurück
- Verkäufe in Nordamerika stiegen um 1 %
Das Unternehmen plant bedeutende Biosimilar-Einführungen im Jahr 2025, darunter Wyost/Jubbonti (Denosumab) in Europa und den USA, Tyruko (Natalizumab) in den USA sowie Afqlir (Aflibercept) in Europa. Die jüngsten US-Regierungszölle umfassen eine 20%ige China-Abgabe, die am 4. März 2025 eingeführt wurde, mit Auswirkungen, die innerhalb der Prognoseerwartungen liegen.
- Q1 2025 net sales grew 5% on comparable growth rate basis
- 14 consecutive quarters of top-line growth achieved
- Ten largest-selling medicines grew by combined 4%, representing 33% of net sales
- Europe net sales grew strongly by 7%
- Biosimilars segment grew 11% (14% CGR), now representing 27% of total sales
- Multiple high-value biosimilar launches planned for H2 2025 including Wyost/Jubbonti and Tyruko
- Company confirmed full-year guidance with mid single-digit net sales growth
- North America sales growth limited to 1%
- International sales declined by 2%
- Price erosion of three percentage points affected overall performance
- Generics segment remained flat with 0% growth (cc)
- Withdrawal of Cimerli product in North America during Q1
- 20% China tariff implemented by US government in March 2025
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
MEDIA RELEASE
- Q1 2025 net sales of USD 2,480 million
- up by
3% in constant currencies (cc); stable in USD - up by
5% [1] at a comparable growth rate (CGR), when adjusted for impact of 2024 acquisition of US biosimilar Cimerli® (ranibizumab) and 2024 divestment of China business - ten largest-selling medicines grew by combined
4% and represented33% of net sales
- up by
- Europe net sales grew by
7% [1]. International declined by2% [1] and increased by2% when adjusted for China divestment. Net sales in North America grew by1% [1] and, adjusted for Cimerli acquisition, by3% - Anticipated biosimilar launches primarily weighted to second half of year. Launches include Wyost®/Jubbonti® (denosumab) in Europe and US, Tyruko® (natalizumab) in US[2] and Afqlir® (aflibercept) in Europe
- Favorable moves towards regulatory streamlining of biosimilar development reflected in decision to minimize pembrolizumab Phase III trial
- Full-year impact of US government’s confirmed recent tariffs within guidance
- Full-year 2025 guidance confirmed: mid single-digit net-sales growth[1] and core EBITDA margin of around
21%
Basel, April 30, 2025 – Sandoz (SIX: SDZ / OTCQX: SDZNY), the global leader in generic and biosimilar medicines, today presents its net-sales update for the first quarter of 2025.
Richard Saynor, Chief Executive Officer of Sandoz, commented: “With Q1 sales in line with our expectations, we have now delivered fourteen consecutive quarters of top-line growth. This reconfirms our growing track record of execution and performance, driven by commercial excellence and an expanding biosimilar pipeline and portfolio, underpinned by our generics base. I’m looking forward to additional growth in the second quarter and further progress this year as we launch more biosimilar medicines.
“With our business continuing to grow, we are confident of delivering more affordable medicines for patients and savings for society, while producing sustainable growth in sales, profitability and cash generation. It is the powerful combination of delivery and pioneering access for patients that makes us proud to be part of the Sandoz growth journey.”
FULL-YEAR 2025 GUIDANCE
The Company expects further major biosimilar launches later this year, while price erosion is expected to return to normalised levels of a low to mid-single-digit percentage. Sandoz anticipates core EBITDA-margin expansion to reflect the mix of sales, simplification of the external network and the ongoing transformation program. As a result, the Company continues to expect:
- FY 2025 net sales to grow by a mid single-digit percentage[3]
- a core EBITDA margin in FY 2025 of around
21%
This guidance excludes any impacts of unforeseen events or unconfirmed developments, such as significant further potential trade tariffs emanating from the US government.
FIRST-QUARTER NET SALES
Net sales for the first quarter amounted to USD 2,480 million, representing growth of
| Q1 2025 | % of Net Sales | Q1 2024 | % change | ||||
| USD m | USD m | USD | cc | CGR[3] | |||
| Generics | 1,809 | 73 | 1,869 | -3 | 0 | 2 | |
| Biosimilars | 671 | 27 | 623 | 8 | 11 | 14 | |
| Net Sales | 2,480 | 100 | 2,492 | 0 | 3 | 5 | |
Generics overview
Net sales for the first quarter were USD 1,809 million, reflecting a stable performance[3] (+
Europe sales of generics grew in the first quarter, driven by the effect of launches in 2024. International net sales declined, with the impact from the divested China business outweighing growth in other markets. In North America, generics’ net-sales growth benefitted from the successful recent launch of paclitaxel.
Biosimilars overview
Net sales for the first quarter were USD 671 million, reflecting growth of
Strong Europe biosimilars’ net-sales growth benefitted from a number of good performances, including Hyrimoz® (adalimumab) and recently launched Pyzchiva® (ustekinumab), while International biosimilar net sales also saw a strong contribution from Omnitrope® (somatropin). North America biosimilar net sales declined, reflecting the withdrawal of Cimerli during the quarter; excluding the impact of the 2024 acquisition Cimerli, North America biosimilar net sales increased.
Net sales by region
| Q1 2025 | % of Net Sales | Q1 2024 | % change | ||||
| USD m | USD m | USD | cc | CGR[4] | |||
| Europe | 1,372 | 55 | 1,326 | 3 | 7 | 7 | |
| International | 590 | 24 | 642 | -8 | -2 | 2 | |
| North America | 518 | 21 | 524 | -1 | 1 | 3 | |
| Net Sales | 2,480 | 100 | 2,492 | 0 | 3 | 5 | |
Europe overview
Net sales for the first quarter amounted to USD 1,372 million, reflecting growth of
Europe net sales of generics grew in the first quarter, with higher growth in biosimilars primarily a result of recent launches, including Pyzchiva.
International overview
Net sales for the first quarter amounted to USD 590 million, reflecting a decline of
Pricing increased in both generics and biosimilars during the quarter, with strong biosimilar net sales partly a result of the continued good performance from Omnitrope.
North America overview
Net sales for the first quarter amounted to USD 518 million, reflecting growth of
A good performance from generics was driven by the successful recent launch of paclitaxel, as well as continued strong growth in Canada. Biosimilar net-sales growth would have been positive when excluding the impact of the 2024 acquisition of Cimerli. Price erosion was driven by reduced Cimerli and private-label adalimumab pricing.
US TARIFFS
The only tariffs applicable to the Company, as part of recent implementation from the US government, is a total
The Sandoz manufacturing footprint consists of 15 sites, including 11 in Europe and one in the US, from which the latter does not export to Europe. US first-quarter net sales represented less than one-fifth of total net Q1 sales.
REGULATORY STREAMLINING: BIOSIMILARS
Reflecting encouraging and favourable developments, Sandoz has decided to minimize its ongoing Phase III trial in patients with untreated metastatic non-squamous non-small cell lung cancer for the proposed biosimilar, pembrolizumab. The ongoing Phase I pharmacokinetic trial is continuing as planned. This decision was partly based on communications with the US FDA, as well as a reflection paper published by the European Medicines Agency. The Company is assessing implications, including for its wider biosimilars pipeline.
In April 2025, Sandoz announced the filing of an antitrust lawsuit in the US against Amgen, Inc. (Amgen), for extending and entrenching the dominant market position of Enbrel®[5] (etanercept), first approved by the US FDA in 1998. Sandoz alleges that Amgen blocked competition from more cost-effective biosimilar competitors, including Sandoz etanercept biosimilar, Erelzi®[6] (etanercept-szzs), by unlawfully purchasing and using certain patent rights to entrench its position in the market.
KEY LINKS
A conference call and webcast for investors and analysts will begin today at 9am CET. Details can be found here, with the accompanying presentation here.
CALENDAR
The Company intends to publish its half-year results on August 7, 2025.
[1] In constant currencies (cc).
[2] Subject to FDA approval of John Cunningham virus assay.
[3] In constant currencies (cc).
[4] In constant currencies (cc).
[5] Enbrel® is a registered trademark of Amgen, Inc.
[6] Erelzi® is a registered trademark of Sandoz, Inc.
CONTACTS
| Media Relations contacts | Investor Relations contacts |
| global.mediarelations@sandoz.com | investor.relations@sandoz.com |
| Alex Kalomparis +41 79 279 02 85 | Craig Marks +44 7818 942 383 |
| Joerg E. Allgaeuer +49 171 838 4838 | Tamara Hackl +41 79 790 52 17 |
| Danja Spring +41 79 156 74 88 | Rupreet Sandhu +41 79 410 54 72 |
DISCLAIMER
This media release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law. This media release includes non-IFRS financial measures as defined by Sandoz. An explanation of non-IFRS measures can be found in the Supplementary financial information of the latest Integrated Annual Report.
ABOUT SANDOZ
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure more than 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion.
| APPENDIX |
QUARTERLY NET SALES
The Company intends to provide the net-sales performance by region by generics/biosimilars at each half-year and full-year results.
FY 2024
| Q1 2024 | % change | Q2 2024 | % change | Q3 2024 | % change | Q4 2024 | % change | |||||||||
| USD m | USD | cc | USD m | USD | cc | USD m | USD | cc | USD m | USD | cc | |||||
| Generics | 1,869 | 0 | 1 | 1,835 | -1 | 1 | 1,854 | 3 | 4 | 1,946 | 1 | 4 | ||||
| Biosimilars | 623 | 21 | 21 | 720 | 35 | 37 | 741 | 36 | 37 | 769 | 23 | 25 | ||||
| Net Sales | 2,492 | 5 | 6 | 2,555 | 7 | 9 | 2,595 | 11 | 12 | 2,715 | 7 | 9 | ||||
| Q1 2024 | % change | Q2 2024 | % change | Q3 2024 | % change | Q4 2024 | % change | |||||||||
| USD m | USD | cc | USD m | USD | cc | USD m | USD | cc | USD m | USD | cc | |||||
| Europe | 1,326 | 4 | 2 | 1,308 | 2 | 3 | 1,362 | 13 | 12 | 1,367 | 7 | 8 | ||||
| International | 642 | 4 | 12 | 627 | 5 | 9 | 635 | 2 | 8 | 653 | 0 | 6 | ||||
| North America | 524 | 6 | 6 | 620 | 22 | 23 | 598 | 17 | 18 | 695 | 13 | 14 | ||||
| Net Sales | 2,492 | 5 | 6 | 2,555 | 7 | 9 | 2,595 | 11 | 12 | 2,715 | 7 | 9 | ||||
Attachment
FAQ
What are Sandoz (SDZNY) Q1 2025 sales numbers and growth rate?
How did Sandoz biosimilars perform in Q1 2025?
What is Sandoz (SDZNY) full-year 2025 guidance?
How will US tariffs impact Sandoz (SDZNY) in 2025?
Which new biosimilars will Sandoz launch in 2025?
